Clinical Trial Update: Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes

View source ↗

Summary

Completed observational study evaluating quality of life and clinical outcomes in people with diabetes treated with NovoMix 30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoMix 30 (insulin aspart protamine fixed-dose combination)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Status: COMPLETED